Argenx shares have risen significantly following positive results from a Phase 3 study of efgartigimod in an autoimmune myositis trial. The promising data indicates potential for the drug in treating the condition.

argenx has reported positive topline results from its Phase 3 ALKIVIA trial, evaluating efgartigimod for the treatment of autoimmune myositis.